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INFECTION—Quality of Life Presentations
PIN17
PRELIMINARY RESULTS OF A U.S.-BASED
STUDY TO VALIDATE THE ACUTE BRONCHITIS
SYMPTOM SEVERITY SCALE
Leidy NK1, Margolis MK1, Merchant S2, Gondek K2,
Li-McLeod J2, Kisken A2, Choudhri S2, Church D2
1MEDTAP International, Bethesda, MD, USA; 2Bayer
Pharmaceutical Corporation, West Haven, CT, USA
OBJECTIVE: To evaluate the psychometric characteris-
tics of the Acute Bronchitis Symptom Severity Scale
(ABSS).
METHODS: The ABSS is a seven-question, bronchitis
speciﬁc, instrument. Responses are measured on a scale
of 0–4. The total score is calculated as the mean of the
seven responses with higher scores indicating greater dis-
tress. The ABSS was pilot tested as a part of a US-based
prospective, naturalistic study to patients with acute exac-
erbation of chronic bronchitis at the pre-treatment visit,
each day of the ﬁrst ﬁve days of therapy with any anti-
microbial agent, and at the test-of-cure visit (TOC, 18–21
days post therapy). Item and total scale performance,
internal consistency (Cronbach’s alpha), construct valid-
ity (correlation with St. George’s Respiratory Question-
naire or SGRQ subscale), and responsiveness to change
over time (based on clinician evaluation and patient’s 
perceived treatment efﬁcacy) were examined.
RESULTS: Twenty-seven patients were enrolled at four
study sites in the US. Mean age was 57.4 (+14.5) years;
74% were female. No ﬂoor or ceiling effects were seen.
Consistent with an improvement in acute bronchitis
symptoms over time, mean item and total score values
declined from baseline to TOC. Cronbach’s alpha at each
time point ranged from 0.70 to 0.88, exceeding the reli-
ability guideline of 0.70 for a new measure. At TOC, the
correlation between the ABSS total score and SGRQ
activity subscale score was strong (0.60). The 18 patients
considered clinically cured or improved at day 5 reported
a mean ABSS score change, from baseline, of -0.90.
Patients who considered the treatment moderately effec-
tive at day 5 (n = 11) reported an average change score
of -0.87, while those who considered the treatment very
effective (n = 3) improved by a score of -1.50.
CONCLUSIONS: Preliminary results from this pilot test
with US-based patients suggest the instrument is valid,
reliable, and sensitive to change over time.
PIN18
THE ASSOCIATION BETWEEN HEALTH
RELATED QUALITY OF LIFE AND ADHERENCE
TO THERAPY IN HEPATITIS C
Green J1,Wintfeld N1, Barker C2, Revicki D3, Bernstein D4
1Hoffman LaRoche Inc, Nutley, NJ, USA; 2MEDTAP, Seattle,
WA, USA; 3MEDTAP International, Inc, Bethesda, MD, USA;
4North Shore University Hospital, Manhasset, NY, USA
For many conditions the overall impact of treatment on
health related quality of life (HRQL) involves a tradeoff
between improvement in the condition being treated and
unwanted side effects. When the net HRQL result is too
negative, patients have difﬁculty tolerating medication
and may fail to adhere or discontinue treatment.
OBJECTIVE: We investigated the association between
reduced HRQL due to interferon treatment and prema-
ture treatment discontinuation for chronic hepatitis C.
METHODS: A pooled secondary analysis of patients (n
= 1441) across three international, multicenter, open-
label, randomized studies that compared peginterferon 
a-2a with interferon a-2a. Health-related quality of life
was assessed using the SF-36 Health Survey. The Fatigue
Severity Scale (FSS) was used to measure the impact of
disabling fatigue. Logistic regression analysis was used 
to examine the association between changes in health-
related quality of life and treatment discontinuation.
RESULTS: Reduction from baseline in HRQL scores was
a signiﬁcant predictor of in-treatment SF-36 scores 
(P < 0.001). The odds of discontinuing treatment early
were 48% higher in the quartile of patients with the great-
est worsening of fatigue scores than in the lowest quar-
tile. The odds ratios for treatment discontinuation among
patients with worsening of SF-36 domain and summary
scores ranged from 1.09 (physical function) to 3.56 (role
limitations-emotional). 
CONCLUSION: The impact on health-related quality of
life is an important consideration in optimizing treatment
of patients with chronic hepatitis C. HRQL assessments
during treatment may offer physicians a method for 
monitoring the risk of premature discontinuation.
PIN19
PRESCRIBING DECISIONS IN A UTILITY MODEL
Shaya FT1, Mullins CD1,Ahn J1, Merchant S2, Corcoran G2,
Church D2
1University of Maryland, Baltimore, MD, USA; 2Bayer
Pharmaceutical Corporation, West Haven, CT, USA
OBJECTIVE: To build a utility-based model comparing
physicians’ prescribing practices for acute sinusitis,
assuming that utility is a function of repeat visits, second
prescriptions and call-backs.
METHODS: An algorithm is applied to data from an
open-label, multicenter, randomized trial, which docu-
ments call back times, ofﬁce visits and second prescrip-
tions for 792 Acute Bacterial Sinusitis patients treated
with Amoxicillin clavulanate 875mg, Levoﬂoxacin 
500mg or Moxiﬂoxacin 400mg. The marginal effect of
fewer call-backs, ofﬁce visits and second prescriptions,
using utility as a function of these, is represented by a
decision tree. Probabilities from the trial are used. Utili-
ties range from highest (1.00) when the patient does not
call back or get a second prescription, to lowest (0.25),
when the patient calls back/comes back for a visit. Inter-
mediate utilities range in decreasing order from call-
back/no action, to no call-back/second prescription, to
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call-back for other reasons, to call-back/second prescrip-
tion. Regardless of the drug prescribed, the utility to the
physician of a given outcome is the same.
RESULTS: Fewer call-backs and repeat visits pursuant 
to moxiﬂoxacin resulted in the highest expected value
(0.90), compared to levoﬂoxacin (0.89) and Amoxicillin
(0.87), when the lowest utility was 0.25. A sensitivity
analysis showed consistent results, with 0.86 for Moxi-
ﬂoxacin, 0.85 for Levoﬂoxacin and 0.82 for Amoxicillin
when the lowest utility was zero. When the lowest utility
was 0.75, all drugs yielded 0.96. 
CONCLUSION: Physicians who seek to reduce events of
call-backs, repeat visits and second prescriptions may
favor certain antibiotic regimens, such as Moxiﬂoxacin,
for the treatment of acute sinusitis. This is more relevant
when physicians put a higher premium on reduced events,
that is when the spread in utilities is larger (0.25 and
1.00), than when the spread is smaller (0.75 and 1.00).
INFECTION—Health Policy Presentations
PIN20
PHYSICIAN PRESCRIBING PATTERNS FOR
PEDIATRIC OTITIS MEDIA IN 
AMBULATORY PATIENTS
Rahman AM1, Feldhaus J2, Lawrence L2, Rappaport H2
1St. John’s University, Jamaica, NY, USA; 2University of
Louisiana at Monroe, Monroe, LA, USA
OBJECTIVES: Appropriate use of antibiotics is a major
healthcare issue in view of increasing worldwide bacterial
resistance to antibiotics. Treatment of otitis media is the
most frequent reason for administering antibiotics to chil-
dren in the United States. This study examined physicians’
prescribing pattern(s) for otitis media in children and
compared them with therapeutic guidelines issued by the
American Academy of Pediatrics, Family Physicians, and
Otolaryngology, for appropriateness.
METHODS: Appropriateness of antibiotics was esti-
mated across patient and physician factors. Patient
factors such as age, sex, race, geographical location and
payment source were compared with physician variables
such as specialty, practice settings, geographic location
and referral status for prescribing appropriateness. Data
from the (1997) National Ambulatory Medical Care
Survey (NAMCS) were utilized. Patients of age less than
or equal to 12 years with a principal diagnosis of otitis
media were analyzed using multiple linear and binomial
logit regression models. Appropriate antibiotics were
deﬁned as those that are recommended by the guidelines.
The dosage of antibiotics was conﬁrmed by IMS Health
Inc. and the advice of a practicing otolaryngologist.
RESULTS: Pediatricians and otolaryngologists prescribed
more appropriate and less expensive antibiotics such 
as amoxicillin, ampicillin and sulfamethoxazole (R2 =
0.144). Internists and family practice physicians pre-
scribed more expensive second line antibiotics (R2 =
0.178). There was no relation between the physician’s
specialty and patient’s age for inappropriate antibiotics
prescribing (R2 = 0.345). The probability of appropriate
prescribing was higher for a physician from the northeast
and midwest than for a physician from the south (R2 =
0.167). Appropriate prescribing was not inﬂuenced by
whether the patient was referred (R2 = 0.456).
CONCLUSIONS: Physician’s specialty inﬂuences antibi-
otics prescribing for otitis media. Otolaryngologists and
pediatricians appear to prescribe appropriately, while
general practice physicians may not be prescribing the
appropriate, less expensive antibiotics.
PIN21
SECOND-LINE THERAPY FOR 
OUTPATIENT TREATMENT FOR 
COMMUNITY-ACQUIRED PNEUMONIA
Singer ME, Jaffe DH
Case Western Reserve University, Cleveland, OH, USA
In the USA, macrolides are the dominant choice for initial
outpatient treatment for community-acquired pneumonia
(CAP). However, there is no consensus on second-line
therapy. Cephalosporins, quinolones, beta-lactams and
other macrolides are all commonly prescribed.
OBJECTIVE: To compare outcomes for different second-
line treatment strategies in outpatient treatment of CAP.
METHODS: We employed a previously developed and
validated probabilistic model to calculate treatment
failure rates for adult CAP with no major comorbidities.
We considered four choices for second-line therapy 
following initial treatment with the macrolide azithro-
mycin (AZI): cefuroxime (CEF), levoﬂoxacin (LEV),
amoxycillin-clavulanate (AMC) and clarithromycin
(CLA). Distribution of causative pathogens was based on
literature. We used surveillance data for the USA from the
1999–2000 PROTEKT study, and applied pharmacoki-
netic/pharmacodynamic breakpoints to determine resis-
tance levels for streptococcus pneumoniae (SP) and
haemophilus inﬂuenzae (HI). Intracellular organisms
were assumed 100% susceptible to CLA, LEV but resis-
tant to CEF, AMC. Other bacteria were assumed 50%
susceptible to all four drugs. We used published estimates
of pathogen-speciﬁc rates of spontaneous resolution. We
assumed 20% of initial treatment failures and 100% of
second-line treatment failures were hospitalized. We esti-
mated that 90% of susceptible organisms would respond
to treatment.
RESULTS: In SP, the most common cause of CAP, there
was substantial cross-resistance between AZI and the
second-line drugs, except for LEV. For example, SP was
86.6% susceptible to CEF when it was susceptible to AZI,
but only 16.3% susceptible to CEF when resistant to AZI.
The model estimated that in 59.5% of cases the initial
treatment with AZI would be successful and 5.9% would
be hospitalized following initial treatment failure. An
additional 5.2% would be hospitalized if treated with
LEV, 9.1% with AMC, 13.3% with CEF and 19.3% with
CLA. 
